• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Bausch + Lomb: The Experts in the Evolution of Bromfenac

Article

Partner Perspectives
What is this?

×

Partner Perspectives allows marketers to connect directly with the Ophthalmology Times audience by enabling them to share their content. This content does not necessarily reflect the views of Ophthalmology Times editorial staff or UBM.

Learn more

Become a partner

PROLENSA® (bromfenac ophthalmic solution) 0.07%

Please see Indication and Important Safety Information for PROLENSA® on video.

Contact us: In order to provide more personalized service, we ask that you report any concerns with Bausch + Lomb Products via phone at 800-553-5340.

Product Concerns: 800-553-5340

Order Inquiries for professionals: 800-828-9030

 

Related Videos
Video 2 - 1 KOL is featured in, "Advances in Technology for SMILE procedure"
Video 1 - 1 KOL is featured in, "Overview of Small Incision Lenticule Extraction (SMILE)"
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.